Breaking News
May 22, 2018 - CSIRO study urges Australians to avoid junk protein foods for healthy weight loss
May 22, 2018 - Breath Test Shows Promise for Diagnosis of Esophagogastric CA
May 22, 2018 - Common class of drugs linked to dementia even when taken 20 years before diagnosis
May 22, 2018 - Optimal Biomarker Frequency for Biosensors
May 22, 2018 - Ethics of conducting clinical research during public health emergencies
May 22, 2018 - FDA Approves Aimovig (erenumab), The First Drug Aimed at Preventing Migraines
May 22, 2018 - Warning labels on alcohol containers highly deficient, new research shows
May 22, 2018 - Doctors publish comprehensive proposal to ensure universal access to safe, affordable medications
May 22, 2018 - When is insurance not really insurance? When you need pricey dental care.
May 22, 2018 - Thyroid tumors may be more susceptible to precisely targeted radiation treatment, suggests study
May 22, 2018 - Researchers uncover clues to early lung transplant failure
May 22, 2018 - Coagulation Factor Tests: MedlinePlus Lab Test Information
May 22, 2018 - Booze ads cause risky drinking in young people
May 22, 2018 - Are you and your primary care doc ready to talk about your DNA?
May 22, 2018 - UCI research team uncovers new unexpected mode of neurotransmitter-based communication
May 22, 2018 - Researcher develops nanoparticle-based tags to detect viruses and cancer with high sensitivity
May 22, 2018 - Researchers highlight need for transgender-inclusive healthcare providers
May 22, 2018 - Celgene to share new and updated data around novel hematological therapies
May 22, 2018 - Scientists identify cell types underlying schizophrenia
May 22, 2018 - ACR urges legislative action on access and cost barriers in rheumatologic care
May 22, 2018 - Study examines link between nicotine dependence and likelihood to quit smoking after lung cancer screening
May 22, 2018 - New report highlights danger of childhood drowning in open water
May 22, 2018 - Proposed definition of patient-centeredness and engagement in healthcare
May 22, 2018 - Scientists reveal likely cause of childhood leukaemia
May 22, 2018 - Specific patterns of fat distribution linked to metabolic disease, shows study
May 22, 2018 - Novel drug prevents memory impairment in mice exposed to simulated deep space radiation
May 22, 2018 - New LIVE scoring tool effectively predicts future risk of hospitalization for COPD patients
May 22, 2018 - Most people with preclinical signs of Alzheimer’s disease may not develop dementia
May 22, 2018 - Fetal MRI can accurately identify holoprosencephaly by 18 weeks of gestation
May 22, 2018 - Multidisciplinary clinic can provide quality care for low-income patients with lung conditions
May 22, 2018 - Researchers create tool to determine patient’s response to immunotherapy drugs
May 22, 2018 - Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers
May 22, 2018 - New technique allows researchers to control heart cells growing in a dish
May 22, 2018 - FDA Approves Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalemia
May 22, 2018 - Making America’s doctors look more like America
May 22, 2018 - Few parents use simple strategies to protect kids from food poisoning, reports study
May 22, 2018 - Reduction in heart disease risk factors could help prevent frailty among older adults
May 22, 2018 - Study finds age-related racial disparities in youth suicide
May 22, 2018 - Childhood leukemia linked to lack of childhood infections
May 22, 2018 - Scientists identify new drug target to combat chikungunya virus
May 22, 2018 - PSCK9 inhibitors may provide benefit to atherosclerosis patients with high lipoprotein(a) levels
May 22, 2018 - Celltrion Healthcare advocates early introduction of biologics for patients to improve clinical outcomes
May 22, 2018 - Local anesthetic drug not linked to reduction in opioid use, complications after knee surgery
May 22, 2018 - FDA Alert: Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement
May 22, 2018 - Post-surgical opioids can, paradoxically, lead to chronic pain
May 22, 2018 - Flow of cerebrospinal fluid found to be key signal for neural stem cell renewal
May 22, 2018 - Nipah virus kills nine in Kerala, India
May 22, 2018 - Higher body temperatures speed the bodies’ responses to infections and tumors, finds research
May 22, 2018 - Staying up all night, sleeping all day can swiftly impact over 100 proteins in the blood
May 22, 2018 - Combination of vascular risk and brain amyloid levels may accelerate age-related cognitive decline
May 22, 2018 - ASCO: Few Eligible Smokers Had CT Screen for Lung CA in 2016
May 22, 2018 - In Brazil, patients risk everything for the ‘right to beauty’
May 22, 2018 - Women with gestational diabetes may be at greater risk for chronic kidney disease
May 22, 2018 - Flavonoid intake may reduce lung function decline that occurs with aging
May 22, 2018 - AACN brings together over thousands of nurses for annual conference
May 22, 2018 - AHA: ‘Ideal’ Heart Health Eludes More Americans
May 22, 2018 - Drug used to treat daytime sleepiness does not appear to improve driving in those with sleep apnea
May 22, 2018 - Incorporation of AI could transform cancer diagnosis in UK
May 22, 2018 - Neurological protein found to protect against inflammatory diseases
May 22, 2018 - Lipoprotein (a) Blood Test: MedlinePlus Lab Test Information
May 22, 2018 - A new molecular target identified in depression
May 22, 2018 - Researchers discover new gene locations that determine heart’s response to exercise
May 21, 2018 - HCM mutation prevents the heart from increasing pumping force, study shows
May 21, 2018 - Intelligent brains possess fewer neuronal connections, finds study
May 21, 2018 - UA physicians developing new tool to detect urethral blockage
May 21, 2018 - Fish-eating habits of pregnant women not linked to autistic traits in their children
May 21, 2018 - Shingrix Shingles Vaccination | What You Should Know
May 21, 2018 - Early depression diagnosis is deadly serious for patients with coronary artery disease
May 21, 2018 - Reducing exposure to hormone interfering chemicals may mitigate obesity risk
May 21, 2018 - Analysis of lymph node dissection shows no overall survival benefit in renal carcinoma patients
May 21, 2018 - FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine
May 21, 2018 - Infant death study reveals dangerous sleep practices among babysitters, relatives, others
May 21, 2018 - Intermittent fasting may increase diabetes risk, shows study
May 21, 2018 - Increase in local temperature correlates with higher degree of antibiotic resistance, finds study
May 21, 2018 - Treg infusions show promise in slowing progression of ALS
May 21, 2018 - New study shows declines in prostate cancer screening, diagnoses and treatment
May 21, 2018 - Fasting diets could raise risk of diabetes say experts
May 21, 2018 - FDA Alert: 7K and Poseidon 4500 by Shoreside Enterprises: Voluntary Recall
May 21, 2018 - Cell phones at summer camp: Research explores the effects
May 21, 2018 - Birth rate decline driven by waiting longer to have children, cost of infertility treatment
New treatment regimen boosts survival for young adults and children with T-cell malignancies

New treatment regimen boosts survival for young adults and children with T-cell malignancies

image_pdfDownload PDFimage_print

ASCO Perspective

“As oncologists, we are constantly striving for better care and outcomes for our patients, even in cancers where survival rates are relatively high compared with others. We now know it’s possible to significantly boost survival in children and young adults with rare forms of leukemia and lymphoma, without introducing additional harsh side effects that can impair their quality of life,” said ASCO President Bruce E. Johnson, MD, FASCO.

In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90% of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84% were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.

The addition of nelarabine (Arranon) to standard chemotherapy provided further benefit for the group of patients with moderate or high risk of T-ALL recurrence — at four years 89% of those who received nelarabine were leukemia-free vs. 83% of those who did not. The study will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.

“T-cell ALL is a disease that requires the use of a very intense and complex chemotherapy regimen. Historically, about 80% of people live at least four years after being treated for their disease, but we felt we could and must do better,” said lead study author Kimberly Dunsmore, MD, professor, Virginia Tech Carilion School of Medicine in Roanoke. “Our trial shows that we could further increase survival rates by about 10%, which is very encouraging.”

About the Study

The trial, begun in 2007, enrolled patients 1-30 years of age with either T-ALL (94% of trial participants) or T-LL (6% of participants). With 1,895 patients, this is the largest randomized clinical trial ever performed in these diseases.

The trial had four arms, with all patients receiving the standard, complex, multi-drug chemotherapy regimen known as COG augmented Berlin-Frankfurt-Munster (aBFM) chemotherapy. In addition to receiving aBFM, patients were randomly assigned to also receive either high-dose methotrexate (a chemotherapy) in a hospital or escalating dose methotrexate (a regimen that starts with low doses of methotrexate, gradually increased over time) in an outpatient setting.

The group of patients with moderate or high risk of cancer recurrence were also randomly assigned to receive or not receive nelarabine, in addition to chemotherapy, and cranial radiation (to prevent or treat brain metastases).

Nelarabine was approved in 2005 by the FDA for the treatment of people with T-ALL and T-LL that had progressed after at least two chemotherapy regimens. Unlike the trials that led to the FDA approval, nelarabine was tested in newly diagnosed patients in this trial.

Key Findings

  • -Overall, 90.2% of patients treated in this trial lived at least four years, and 84.3% had no sign of cancer at four years.

    -In the group of patients with T-ALL who had increased risk of recurrence, 88.9% of those who received nelarabine were leukemia-free at four years compared to 83.3% of those not treated with nelarabine.

    -While patients with T-LL did not benefit from the addition of nelarabine, more than 85% lived for four years without signs of disease.

    -Contrary to results from previous, smaller trials, patients with T-ALL who received escalating doses of methotrexate did better than those who received high-dose methotrexate (four-year disease-free survival with escalating dose was 89.8% vs. 78% with high-dose).

    -Among T-ALL patients randomly assigned to receive both nelarabine and escalating doses of methotrexate, 92.2% were leukemia-free at four years.

    -Patients who did not have cancer remission following the initial (induction) phase of chemotherapy were assigned to receive high-dose methotrexate and nelarabine; 54.8% of survived four years without signs of the disease. This is a significant improvement, as historically only about 20% of people with T-ALL who did not experience cancer remission lived another three years, according to the authors.

Next Steps

Most doctors are moving to decreasing the use of cranial radiation for T-cell leukemia as late side effects can occur after cranial radiation. Late side effects include changes in cognitive abilities, learning disabilities, neuroendocrine changes, and development of secondary malignancy. The next step will be for clinicians to examine the implications and benefits that may accrue when using nelarabine in chemotherapy protocols without cranial radiation.

Source:

https://www.asco.org/about-asco/press-center/news-releases/new-regimens-improve-survival-children-and-young-adults-t-cell

Tagged with:

About author

Related Articles